LDLR and hyperlipidemia: There was evidence that the inhibition of mTOR inhibitors led to an increase of PCSK9 expression by regulating PKCδ, HNF4α, and HNF1α, a decrease of hepatic LDLR protein levels, and an increase of VLDL/LDL cholesterol levels in mice, ultimately leading to hyperlipidemia [28].